The Footnote

The trillion-dollar trap: unpacking the global cost of diabetes

Humanity poured US $1.015 trillion into diabetes care and complications in 2024—12 % of every health-care dollar spent on Earth, a figure that has ballooned 338 % since 2007.(1,2) Put differently, diabetes now consumes more money each year than Apple or the entire global airline industry earns in revenue.

Author attribution not recorded

A cracked ceramic piggy bank held by a small bandage amid overflowing coins.

An invoice bigger than Big Tech

Humanity poured US $1.015 trillion into diabetes care and complications in 2024—12 % of every health-care dollar spent on Earth, a figure that has ballooned 338 % since 2007.(1,2) Put differently, diabetes now consumes more money each year than Apple or the entire global airline industry earns in revenue.

Yet money is only half the ledger. The International Diabetes Federation (IDF) counts 589 million adults—one in nine—living with diabetes in 2024 and forecasts 853 million by 2050. (3) The same data show 3.4 million deaths in 2024—one every six seconds, (4) while 252 million people (43 %) remain undiagnosed, the majority in low- and middle-income countries (LMICs).(3)

 

Where the money goes

Direct medical costs. In the United States alone, diabetes devoured US $412.9 billion in 2022—about one in every four health-care dollars.(5) Drugs and diabetes supplies made up 17 % of that bill, but hospital care swallowed nearly 40 %.

Indirect costs. The World Health Organization (WHO) projects US $1.7 trillion in lost global GDP between 2011 and 2030 from reduced productivity, disability, and early death due to diabetes.(6)

Intangible costs. Chronic fatigue, anxiety, depression, blindness, dialysis, limb loss and families pushed into catastrophic out-of-pocket spending rarely appear in spreadsheets but dominate the lived experience of the disease.

 

Why the meter keeps spinning faster

Urbanisation, ageing populations and sedentary work expand the pool of high-risk individuals faster than health systems can respond. Ultra-processed foods, sugary drinks and built environments that discourage physical activity fuel obesity. Meanwhile, three multinational companies still control most of the world’s insulin supply, keeping prices out of reach for millions despite a 2021 World Health Assembly resolution calling for equitable access. (7)

 

Regional snapshots

North America & Caribbean – At US $439 billion, the region accounts for 43 % of global diabetes spending despite hosting just 56 million people with the disease.(8) Prevalence has plateaued, but costs continue to climb because of high service prices and expensive technology adoption.

China – With more than 116 million adults affected, China bears the world’s largest national caseload. A 2023 Lancet Regional Health modelling study projects diabetes costs will rise from 1.58 % to 1.69 % of national GDP between 2020 and 2030, outpacing economic growth.(9)

India – A 2024 RSSDI white paper estimates annual diabetes management costs will hit US $12.8 billion by 2030, with out-of-pocket payments often exceeding half of household income.(10)

Sub-Saharan Africa – The region experiences the fastest growth in incidence yet has the lowest treatment coverage; stock-outs of insulin and test strips are common, and foot-ulcer mortality and amputation rates remain far higher than in high-income settings. (4)

 

The iceberg beneath the surface: complications that bankrupt

Diabetic foot ulcers (DFU). A single hospital admission costs US $22 000–28 000 in North America and €15 235 in Spain.(11) Lifetime ulcer risk for anyone with diabetes lies between 19 % and 34 %.(12)

Amputation. A below-knee amputation averages US $70 000 for surgery and early rehabilitation, while each prosthesis adds ≈ US $40 000 every three-to-five years.(13)

Cardio-renal cascade. Dialysis costs tens of thousands of dollars per person per year in high-income countries and is unavailable to most who need it in LMICs.

 

Prevention really is cheaper than cure

Modelling for the World Diabetes Foundation (WDF) shows that an extra US $140 billion spread over 2023-2030—about US $18 billion per year—could avert 39 million deaths and generate US $2.7 trillion in net economic benefit, a 19-to-1 return on investment. (14)

What works? Taxes on sugar-sweetened beverages, front-of-pack warning labels, walkable city design, nurse-led foot-screening programmes, community-health-worker networks using smartphone retinal cameras, and letting allied-health professionals practise at full scope all deliver impressive cost-effectiveness.

 

Feet first: the cost-savings paradox

Foot care is the textbook example: multidisciplinary clinics led by podiatrists cut major amputations by 50-80 % and shave thousands of dollars off each episode of care.(11) In LMIC pilot sites, community health-worker programmes that inspect feet visually and teach basic self-care reduce hospitalisations by about 30 % at a cost of < US $5 per person screened.

 

Technology: promise and peril

Continuous glucose monitors (CGMs), smart pens and closed-loop pumps can cut time in hypo- and hyper-glycaemia by double-digit percentages, but 80 % of CGM sales occur in the richest fifth of countries, widening the digital—and clinical—divide. Conversely, low-tech wins such as offloading sandals, salt-water footbaths and solar-powered vaccine fridges often produce the steepest returns in resource-constrained settings.

 

Five prescriptions for ministries, insurers and industry

  1. Tax what feeds the epidemic. Soda levies and junk-food marketing restrictions curb intake while raising revenue for prevention.

  2. Pay for prevention. Make lifestyle programmes, annual foot and eye checks, and diabetes education reimbursable, not optional.

  3. Unlock allied-health scope. Authorise podiatrists, dietitians, diabetes educators and pharmacists to prescribe and adjust therapies within protocols.

  4. Tame drug prices. Use pooled procurement, biosimilar tendering and patent-flexibility provisions to bring insulin within reach everywhere.

  5. Measure what matters. Publicly report foot-ulcer healing rates, HbA1c control, catastrophic household spending and amputations per 1 000 people with diabetes.

 

The bottom line

Diabetes is no longer just a clinical condition; it is a macro-economic emergency. Every 24 hours we delay scaling equitable prevention and care, another ≈ US $2.8 billion evaporates—and the meter keeps climbing by the heartbeat.(2) The tools to bend both the glucose curve and the cost curve already exist; the true question is whether governments, industry and civil society have the collective will to sign the smaller cheque now—or the far larger one later.

 

References

  1. International Diabetes Federation. Total diabetes-related health expenditure, 2024. IDF Diabetes Atlas data portal; 2025.

  2. International Diabetes Federation. Global Diabetes Data & Insights – Global profile. IDF Diabetes Atlas; 2025.

  3. International Diabetes Federation. IDF Diabetes Atlas. 11th ed. Brussels: IDF; 2025.

  4. International Diabetes Federation. IDF Atlas Global Factsheet 2025. Brussels: IDF; 2025.

  5. American Diabetes Association. Economic costs of diabetes in the United States in 2022. Diabetes Care. 2023;47(1):26-35.

  6. World Health Organization. Global report on diabetes. Geneva: WHO; 2016.

  7. World Health Assembly. Resolution WHA74.4: Strengthening prevention and control of diabetes. Geneva: WHO; 2021.

  8. International Diabetes Federation. North America & Caribbean Regional Data. IDF Diabetes Atlas; 2025.

  9. Xu Y, Zhang X, Li J, et al. Projected rapid growth in diabetes disease and economic burden in China: 2020–2030. Lancet Reg Health – West Pac. 2023;33:100700.

  10. Research Society for the Study of Diabetes in India. White paper on diabetes in India: current status, challenges and future vision. New Delhi: RSSDI; 2024.

  11. Pérez-Montes P, García-Morales E, et al. Economic impact of implementing a multidisciplinary diabetic foot clinic in a tertiary hospital. Int J Diab Foot Care. 2024;8(2):45-54.

  12. McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, epidemiology and disparities in the burden of diabetic foot ulcers. Diabetes Care. 2023;46:209-221.

  13. Wound Care Alliance. The hidden costs of amputations. WCA Briefing; 2024.

  14. World Diabetes Foundation. Strategy 2025-2030: Scaling for impact. Bagsværd: WDF; 2025.

Simplified complete reading view